HalcyGen works on IND

By Dylan Bushell-Embling
Friday, 18 July, 2008

Generic drugs company HalcyGen Pharmaceuticals [ASX: HGN] has completed recruitment and dosing for the first of three pharmacokinetic trials of its SUBA-Itraconazole anti-fungal agent.

The trials, part of the company's Investigational New Drug (IND) application for the product, will examine the absorption, distribution, metabolism and excretion of SUBA-Itraconazole.

It will compare SUBA-Itraconazole directly to the itraconazole market-leader Sporanox, which was developed by Johnson and Johnson subsidiary Janssen Pharmaceuticals.

According to HalcyGen, early trials of SUBA-Itraconazole have already demonstrated increased bioavailability compared to Sporanox.

Related News

How brain stem cells move between resting and active states

Understanding this process is crucial, because it underpins how the brain repairs itself and...

Accurate age estimation with DNA methylation

Using cutting-edge artificial intelligence, scientists created a tool that can determine a...

Algae unlocks a more ethical way to grow cells

Researchers have combined a new type of Queensland algae, Chlorella sp. BDH-1, with...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd